华泰联合证券有限责任公司 关于普蕊斯（上海）医药科技开发股份有限公司 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等有关法律法规的要求，华泰联合证券有限责任 公司（以下简称"保荐人"）作为普蕊斯（上海）医药科技开发股份有限公司（以 下简称"普蕊斯"、"公司"）首次公开发行股票并在创业板上市的保荐人，认真 履行保荐人职责，于 2025 年 8 月 22 日对普蕊斯 2025 年半年度有关情况进行了 现场检查，报告如下： 保荐人名称：华泰联合证券有限责任公司 被保荐公司简称：普蕊斯 保荐代表人姓名：徐妍薇 联系电话：010-56839300 保荐代表人姓名：李 皓 联系电话：010-56839300 现场检查人员姓名：徐妍薇、李 皓 现场检查对应期间：2025年半年度 现场检查时间：2025年8月22日 一、现场检查事项 现场检查意见 （一）公司治理 是 否 不适用 现场检查手段：1.查阅公司工商登记文件、公司章程和公司治理相关制度；2.查阅三会文件及 相关决议，核查其执行情况；3.核查董监高人员变动及相关决策文件、公告文件；4.核查控股股东、 实际控制人是 ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-045 安徽万邦医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开情况 （1）现场会议召开时间：2025 年 8 月 21 日（星期四）下午 14:30。 （2）网络投票时间：通过深圳证券交易所互联网投票系统进行网络投票的 时间为：2025 年 8 月 21 日（星期四）9:15-15:00 期间的任意时间；通过深圳证 券交易所交易系统进行网络投票的时间为 2025 年 8 月 21 日（星期四）上午 楼会议室。 《上市公司股东会 规则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规 章、规范性文件和《安徽万邦医药科技股份有限公司章程》的有关规定。 （二）会议出席情况 截至本次股东大会股权登记日 2025 年 8 月 15 日（星期五），公司总股本为 出席本次股东大会现场会议和网络投票表决的股东及股东授权委托代表共 总数 66,261,767 股的 62.8712%。 其中：通过现场投票的股东及股东授权委托代表 ...

安徽承义律师事务所 安徽承义律师事务所 法律意 见书 关于安徽万邦医药科技股份有限公司 法律意见书 安徽承义律师事务所 ANHUI CHENGYI LAW FIRM 地址： 合肥市政务区怀宁路 200 号栢悦中心大厦五楼、八楼 邮编：230071 电话：0551-65609815 传真：0551-65608051 安徽承义律师事务所 法律意见书 安徽承义律师事务所 关于安徽万邦医药科技股份有限公司 (2025)承义法字第 00197 号 致：安徽万邦医药科技股份有限公司 安徽承义律师事务所（以下称"本所"）接受安徽万邦医药科技股份有限公司（以 下称"公司"）的委托，指派本律师以现场结合视频方式出席公司 2025 年第二次临 时股东大会（以下称"本次股东大会"），对本次股东大会的合法性进行见证。 本律师根据《中华人民共和国公司法》（以下称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下称"《股 东会规则》"）等法律、法规及其它规范性文件和《安徽万邦医药科技股份有限公司 章程》（以下称"《公司章程》"）的规定，就公司本次股东大会的召集、召开程序、 出席会议人员的 ...

证券代码：688393 证券简称：安必平 公告编号：2025-039 广州安必平医药科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州安必平医药科技股份有限公司（以下简称"公司"）已于 2025 年 08 月 四)09:00-10:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 重要内容提示： ??会议召开时间：2025 年 08 月 28 日(星期四) 09:00-10:00 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 ? 会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ??投资者可于 2025 年 08 月 22 日(星期五)至 08 月 27 日(星期三)16:0 ...

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The company, Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., has recently obtained CE certification for five of its products, allowing them to be sold in the EU and European Economic Area (EEA) markets [1] - The certification will facilitate entry into other international markets that recognize or reference EU standards, thereby broadening the overseas application scenarios for the company's products [1] - The company has also secured market access qualifications in multiple countries and regions, including Japan, Ukraine, Ecuador, and Vietnam, and plans to accelerate its international expansion [1]

Core Points - The legal opinion letter confirms the legality of the convening and voting procedures of the second extraordinary general meeting of shareholders of Proris (Shanghai) Pharmaceutical Technology Development Co., Ltd. in 2025 [2][6] - The meeting was convened by the board of directors and held on July 21, 2025, with a combination of on-site and online voting [3][5] - The total number of shareholders present at the meeting was 126, representing 41,496,106 shares, which accounted for 52.1947% of the total shares [5] Meeting Procedures - The meeting was called by the board of directors and the notice was published on the Shenzhen Stock Exchange and other platforms on July 5, 2025 [3][5] - The meeting was held at the World Trade Center in Shanghai and was presided over by the chairman of Proris, Lai Chunbao [3][5] - Voting was conducted through both on-site and online methods, with specific time slots allocated for online voting [3][5] Voting Results - The first resolution regarding participation in the auction and establishment of real estate equity and corresponding debt was approved with 41,400,571 votes in favor, representing 99.7698% of the votes [6] - The second resolution concerning financial assistance to a proposed equity investment company was also approved with 41,374,691 votes in favor, representing 99.7074% of the votes [6] - The voting process was monitored and verified, ensuring compliance with legal and regulatory requirements [6]

Group 1 - The core point of the news is that Norsg (Beijing) Pharmaceutical Technology Co., Ltd. has applied for a patent for an automatic patient information processing system and method, which aims to enhance the accuracy of clinical drug trials and ensure patient safety [1] - The patent application was filed on June 2025, and the public announcement number is CN120260781A [1] - The method described in the patent involves several steps, including gathering historical case information, selecting suitable trial patients, assessing their safety levels, and categorizing trial data [1] Group 2 - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. was established in 2008 and is based in Beijing, focusing on research and experimental development [2] - The company has a registered capital of 96.581256 million RMB and has made investments in 7 enterprises [2] - Norsg has participated in 10 bidding projects and holds 7 trademark registrations and 2 patent registrations, along with 3 administrative licenses [2]

Group 1 - The company held its 13th meeting of the third Supervisory Board on July 4, 2025, with all three supervisors participating, confirming the legality and validity of the meeting [1][2] - The Supervisory Board unanimously approved a resolution to participate in the auction for a 45% stake and corresponding debt of He Li Real Estate, aiming to improve operational efficiency and address office space constraints [1][2] - The company plans to acquire the real estate located at 1010-1016 Wai Ma Road, Huangpu District, Shanghai, with a land area of 1,492.20 square meters, to enhance its office space [1] Group 2 - The Supervisory Board also approved a resolution to provide financial assistance to He Li Real Estate, which has a good credit standing and low default risk, ensuring no harm to the company's main business or shareholder interests [2] - The financial assistance will be in the form of loans to support He Li Real Estate's daily operations and development [2]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders on July 21, 2025, at 14:50 [1] - Network voting will be available on the same day from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 through the Shenzhen Stock Exchange trading system [1] Voting Procedures - Shareholders can choose between on-site voting or network voting, but not both; the first vote will be considered valid in case of duplicate voting [2] - Shareholders must be registered by the cut-off date of July 14, 2025, to participate in the meeting [2][3] Registration Details - Individual shareholders must present identification and stock account information for registration; authorized representatives must provide additional documentation [3][4] - Remote shareholders can register via email, fax, or mail, with a deadline of July 17, 2025, at 17:00 [4] Voting Process - All proposals for the meeting are non-cumulative voting proposals, and shareholders must indicate their voting preference as agree, oppose, or abstain [5][8] - Specific procedures for voting through the Shenzhen Stock Exchange trading system and internet voting system are provided [5] Additional Information - The company has provided templates for the authorization letter and shareholder registration form in the attachments [6][8]